ID: ALA161517

Max Phase: Preclinical

Molecular Formula: C11H10BrN3O2

Molecular Weight: 296.12

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Oc1nc(O)c(Br)c(NCc2ccccc2)n1

Standard InChI:  InChI=1S/C11H10BrN3O2/c12-8-9(14-11(17)15-10(8)16)13-6-7-4-2-1-3-5-7/h1-5H,6H2,(H3,13,14,15,16,17)

Standard InChI Key:  SLPLXDQXLWOWDS-UHFFFAOYSA-N

Associated Targets(non-human)

DNA topoisomerase III 145 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 296.12Molecular Weight (Monoisotopic): 294.9956AlogP: 2.26#Rotatable Bonds: 3
Polar Surface Area: 78.27Molecular Species: NEUTRALHBA: 5HBD: 3
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 11.05CX Basic pKa: CX LogP: 3.28CX LogD: 3.28
Aromatic Rings: 2Heavy Atoms: 17QED Weighted: 0.81Np Likeness Score: -0.78

References

1. Trantolo DJ, Wright GE, Brown NC..  (1986)  Inhibitors of Bacillus subtilis DNA polymerase III. Influence of modifications in the pyrimidine ring of anilino- and (benzylamino)pyrimidines.,  29  (5): [PMID:3084785] [10.1021/jm00155a016]

Source